Search
Molecular Partners AG
MOLNAdd to Watchlist
3.980USD
+0.050+1.27%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
149.29MMarket Cap
LossP/E TTM
More Details of Molecular Partners AG Company
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Molecular Partners AG Info
Ticker SymbolMOLN
Company nameMolecular Partners AG
IPO dateOct 22, 2014
CEOAmstutz (Patrick)
Number of employees159
Security typeDepository Receipt
Fiscal year-endOct 22
AddressWagistrasse 14
CitySCHLIEREN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountrySwitzerland
Postal code8952
Phone41447557700
Websitehttps://www.molecularpartners.com/
Ticker SymbolMOLN
IPO dateOct 22, 2014
CEOAmstutz (Patrick)
Company Executives of Molecular Partners AG
Name
Name/Position
Position
Shareholding
Change
Dr. Michael Tobias Stumpp, Ph.D.
Dr. Michael Tobias Stumpp, Ph.D.
Executive Vice President - Projects, Member of the Management Board
Executive Vice President - Projects, Member of the Management Board
--
--
Dr. Patrick Amstutz, Ph.D.
Dr. Patrick Amstutz, Ph.D.
Chief Executive Officer, Executive Director, Member of the Management Board
Chief Executive Officer, Executive Director, Member of the Management Board
--
--
Mr. Steven H. (Steve) Holtzman, Ph.D.
Mr. Steven H. (Steve) Holtzman, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William M. (Bill) Burns
Mr. William M. (Bill) Burns
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Seth D. Lewis
Mr. Seth D. Lewis
Senior Vice President - Investor Relations and Strategy
Senior Vice President - Investor Relations and Strategy
--
--
Mr. Sandip S. Kapadia, CPA
Mr. Sandip S. Kapadia, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Vito J. Palombella, Ph.D.
Dr. Vito J. Palombella, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Michael Vasconcelles, M.D.
Dr. Michael Vasconcelles, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Agnete B. Fredriksen, Ph.D.
Dr. Agnete B. Fredriksen, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Dominik Hoechli, M.D.
Dr. Dominik Hoechli, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Michael Tobias Stumpp, Ph.D.
Dr. Michael Tobias Stumpp, Ph.D.
Executive Vice President - Projects, Member of the Management Board
Executive Vice President - Projects, Member of the Management Board
--
--
Dr. Patrick Amstutz, Ph.D.
Dr. Patrick Amstutz, Ph.D.
Chief Executive Officer, Executive Director, Member of the Management Board
Chief Executive Officer, Executive Director, Member of the Management Board
--
--
Mr. Steven H. (Steve) Holtzman, Ph.D.
Mr. Steven H. (Steve) Holtzman, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William M. (Bill) Burns
Mr. William M. (Bill) Burns
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Seth D. Lewis
Mr. Seth D. Lewis
Senior Vice President - Investor Relations and Strategy
Senior Vice President - Investor Relations and Strategy
--
--
Mr. Sandip S. Kapadia, CPA
Mr. Sandip S. Kapadia, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
FAQs
Who are the top five shareholders of Molecular Partners AG?
The top five shareholders of Molecular Partners AG are: Dr. Michael Tobias Stumpp, Ph.D.
How many institutions hold shares of Molecular Partners AG (MOLN)?
As of 2026Q1, 14 institutions hold shares of Molecular Partners AG, with a combined market value of approximately 3.59M, accounting for 9.60% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -12188.00.